Neuroscience experts advising the Food and Drug Administration found that a study didn’t provide sufficient evidence that Amylyx Pharmaceuticals Inc.’s experimental amyotrophic lateral sclerosis drug works.
Their 6-to-4 vote on Wednesday sets up a new test for the FDA as it considers approving the latest experimental drug promising to slow the march of the debilitating neurodegenerative disease.
To Read the Full Story
